Breaking News, Collaborations & Alliances

Almirall, Absci Partner on AI Drug Discovery for Dermatology

Collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for chronic inflammatory diseases.

Almirall S.A., a global biopharmaceutical company focused on dermatology, and Absci Corporation, a generative AI drug creation company, entered into a drug discovery partnership to develop and commercialize AI-designed therapeutics for chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation platform with Almirall’s dermatological expertise with the goal of delivering medicines to patients. Absci will apply its de novo generative AI technolog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters